On the other hand, SLE, like PNH, is characterised by complement activation and thrombogenesis, which can explain, to some extent, our finding that patients with thrombosis are likely to have higher SLC15A4 or ABCA13 mutation incidence than patients without thrombosis. Here, SLC15A4 is linked to deep vein thrombosis.